Gilead dives into ‘in vivo’ cell therapy with $350M buyout of Interius
Written by
BioPharma Dive
Published
0
comments
0
min
The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could that potentially widen access to CAR-T treatment.